August 2011 
Volume 41  Number 8
Pages 16 - 16
  PDF Version Available!

Because of increased risk of myopathy, the FDA is recommending that healthcare providers restrict the use of the highest-approved dose (80 mg) of the HMG-CoA reductase inhibitor simvastatin. The new recommendations call for lower starting dosages in new patients; the 80-mg dose should be given only to patients who've been taking the high dose for 1 year or more without any evidence of myopathy.The changes are the result of the FDA's review of a 7-year study that compared the efficacy and safety of 80 and 20 mg simvastatin dosages, with or without vitamin B12 and folate, in patients who'd had a myocardial infarction. Fifty-two patients (0.9%) taking 80 mg developed myopathy, which was higher than the labeled risk of 0.53%. The risks for myopathy in patients taking 80 mg were highest in the first year of treatment.The FDA is also requiring changes to the drug label that add new contraindications and dose limitations for simvastatin when used with other medications.Source: FDA drug safety

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events